ABSTRACT: Two different structures of zeolites, faujasite (FAU) 11 and Linde type A (LTA), were studied to investigate their suitability 12 for drug delivery systems (DDS). The zeolites in the sodium form 13 (NaY and NaA) were used as hosts for encapsulation of α-cyano-4- 
zeolites alone revealed no toxicity to HCT-15 cancer cells. Importantly, CHC@zeolite exhibit an inhibition of cell viability up to 23 585-fold, when compared to the non-encapsulated drug. These results indicate the potential of the zeolites for drug loading and 24 delivery into cancer cells to induce cell death. Preparation and Characterization of DDS. In the 234 present study, the anticancer drug CHC was chosen to test 235 the use of zeolite structures as DDSs. The approach for the 236 preparation of DDS was the adsorption of CHC as a guest in 237 liquid phase within the framework of the zeolite as a host. This 238 approach required that the drug diffused inward the space 239 available of the zeolite framework and the starting zeolites were 240 not cytotoxic to the HCT-15 cell line. In this cell line, 241 preliminary studies with NaY, NaMOR, NaA, and ZSM5 were 242 also carried out. NaY (Faujasite) and NaA structures (Linde 243 type A) showed to be nontoxic to the cells. of crystallinity, while for NaA the crystallinity was ca. 75%.
287
The morphology of the DDS obtained after the encapsula- The Journal of Physical Chemistry C The integrity of the CHC in zeolites was confirmed by the 308 analytical data of carbon and nitrogen content obtained by 309 elemental analysis. The theoretical C/N ratio for CHC is 8.6 310 (63.49% to C and 7.40% to N). All samples based in different 311 zeolites present a similar C/N ratio. For example, the guest C/ 312 N ratio obtained for CHC@Y 1:10 is 8.7 (1.66% to C and 0.19% 313 to N) and for CHC@A 1:10 it is 8.3 (1.49% to C and 0.18% to 314 N), indicating the presence of the molecular drug structure in 315 the zeolite.
316
Evidence for the interaction between CHC and the zeolites is 317 forthcoming from spectroscopic data. The presence of the drug and its interactions in both zeolites The Journal of Physical Chemistry C . No shift or broadening in 371 the principal zeolite vibrational bands occur upon inclusion of 372 the drug, further substantiating that the zeolite framework 373 remains unchanged. Although the characteristic CHC FTIR 374 vibrational bands in the CHC@zeolite spectra are weak, they 375 provide evidence for the presence of drug in the zeolite. Due to 376 overlap with the strong bands arising from the zeolite 377 framework, it is not possible to draw any further conclusions 378 from these data. NMR spectroscopy is, thus, much more 379 sensitive to molecule structural changes than is FTIR. CHC final assay concentrations are presented in Table 2 . 387 To be considered as suitable DDS, zeolites themselves 388 should present small or no effect on cell viability. The The cytotoxic effect of DDS with NaY was more pronounced 407 for higher concentrations of CHC; however, the effect appears 408 not to be directly proportional to the concentrations of the 409 zeolite suspensions. For CHC@NaA, the cytotoxicity was not 410 as high as for NaY zeolite, a reduction of cell viability from 82% 411 to 66% was obtained when comparing with cells treated with f7 412 the starting zeolite (Figure 7) . 
